Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 9, 1996, Pages 739-751

  Kiriyama, A ^a   Nishiura, T ^a   Ishino, M ^a   Yamamoto, Y ^a   Ogita, I ^a   Kiso, Y ^a   Takada, K ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

1 acid glycoprotein; albumin; anti AIDS drug; HIV 1 protease inhibitor; KNI 272; plasma; protein binding; Scatchard plot

Indexed keywords

DIAZEPAM; DIGITOXIN; DISOPYRAMIDE; KYNOSTATIN 272; PLASMA PROTEIN; PROTEINASE INHIBITOR; TRIPEPTIDE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; NONHUMAN; PLASMA PROTEIN BINDING; RAT;

ANIMALS; BINDING, COMPETITIVE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAZEPAM; DIGITOXIN; DISOPYRAMIDE; HIV PROTEASE INHIBITORS; HUMANS; OLIGOPEPTIDES; OROSOMUCOID; PROTEIN BINDING; RATS; SERUM ALBUMIN; WARFARIN;

EID: 0029969768     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199612)17:9<739::AID-BDD987>3.0.CO;2-0     Document Type: Article

References (23)

1. C. Debouck and B. W. Metcalf, Human immunodeficiency virus protease: a target for AIDS therapy. Drug Dev. Res., 21, 1-17 (1990).
2. T. Mimoto, J. Imai, S. Kisanuki, H. Enomoto, N. Hattori, K. Akaji and Y. Kiso, Kynostatine (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstratine. Chem. Pharm. Bull., 40, 2251-2253 (1992).
3. S. Kageyama, T. Mimoto, Y. Murakawa, M. Nomizu, H. Ford, Jr, T. Shirasaka, S. Gulnik, J. Erickson, K. Takada, H. Hayashi, S. Broder, Y. Kiso and H. Mitsuya, In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetric HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother., 37, 810-817 (1993).
4. A. Kiriyama, T. Mimoto, S. Kisanuki, Y. Kiso and K. Takada, Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations. Biopharm. Drug Disposit., 14, 697-707 (1993).
5. M. Sugahara, A. Kiriyama, Y. Hamada, Y. Kiso and K. Takada, Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of dose. Biopharm. Drug Disposit., in press.
6. A. Kiriyama, T. Mimoto, Y. Kiso and K. Takada, Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations. Biopharm. Drug Disposit., 14, 199-207 (1993).
7. J. A. Martin, Ro 31-8959/003. Drugs Future, 16, 210-212 (1991).
8. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother., 35, 2209-2214 (1991).
9. A. Kiriyama, K. Fujita, S. Takemura, H. Kuramoto, Y. Kiso and K. Takada, Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration. Biopharm. Drug Disposit., 15, 617-626 (1994).
10. P. J. McNamara, Interspecies scaling in pharmacokinetics. Drugs Pharm. Sci., 48, 267-300 (1991).
11. A. Bernareggi and M. Rowland, Physiologic modeling of cyclosporin kinetics in rat and man. J. Pharmacokinet. Biopharm., 19, 21-50 (1991).
12. 1-acid glycoprotein in man and other species. Biochem. Pharmacol., 33, 2065-2069 (1984).
13. J. J. Lima and D. B. Haughey, Disopyramide binding to serum protein in man and animals. Drug Metab. Disposit., 9, 582-583 (1981).
14. M. Wood, Plasma drug binding: implications for anesthesiologists. Anesth. Analg., 65, 786-804 (1986).
15. G. Sudlow, D. J. Birkett and D. N. Wade, The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol., 11, 824-832 (1975).
16. G. Sudlow, D. J. Birkett and D. N. Wade, Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol., 12, 1052-1061 (1976).
17. S. Goya, A. Takadake, H. Fujino, M. Otagiri and K. Uekama, New fluorescence probes for drug-albumin interaction studies. Chem. Pharm. Bull., 30, 1363-1369 (1982).
18. I. Sjöholm, B. Ekman, A. Kober, I. Ljungstedt-Påhlman, B. Seiving and T. Sjödin, Binding of drugs to human serum albumin: XI: the specificity of three binding sites as studied with albumin immobilized in microparticles. Mol. Pharmacol., 16, 767-777 (1979).
19. M. Otagiri, Structure and function of serum albumin. Metab. Dis., 22, 1207-1215 (1985).
20. 2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother., 39, 1559-1564 (1995).
21. U. Kragh-Hansen, Molecular aspects of ligand binding to serum albumin. Pharmacol. Rev., 33, 17-53 (1981).
22. S. Kageyama, B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora and H. Mitsuya, Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother., 38, 1107-1111 (1994).
23. 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine. J. Acquired Immune Defic. Syndr., 6, 531-533 (1993).